Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets a portfolio of various products that serves a global customer base. The segment is focused on specific segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology and food safety. Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Its products address specific niches within the in vitro diagnostics (IVD) test market.
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
|Date||Event description||Earnings per|
|May 4, 2023||Q1 2023 Earnings Release||$3.34||$3.21 to $4.08||$4.94|
|February 16, 2023||Q4 2022 Earnings Release||$3.31||$3.34 to $3.62||$3.21|
|October 27, 2022||Q3 2022 Earnings Release||$2.60||$2.59 to $3.01||$3.71|
|July 28, 2022||Q2 2022 Earnings Release||$3.38||$2.46 to $2.98||$3.54|
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.